Skip to main content
SpringerLink
Log in

BRAFV600E mutation and its association with clinicopathological features of papillary thyroid microcarcinoma: A meta-analysis

  • Published:
Journal of Huazhong University of Science and Technology [Medical Sciences] Aims and scope Submit manuscript

Summary

Recent studies have demonstrated that the BRAFV600E mutation is associated with aggressive clinicopathological features of papillary thyroid carcinoma (PTC). However, the BRAF mutation as a prognostic biomarker in papillary thyroid microcarcinoma (PTMC) is unclear. A systematic search of the electronic databases, including Medline, Scopus, CNKI and the Cochrane Library was performed up to July 1, 2014. Outcomes of interest included age, gender, concomitant hashimoto thyroiditis or nodular goiter, tumor size, pathological stage, tall cell variant of PTMC (TCVPTMC), multifocality, extrathyroidal extension (ETE) and lymph node metastasis (LNM). A total of 19 studies published from 2008 to 2014 comprising 2253 patients fulfilled the inclusion criteria and were included in the meta-analysis, and 1143 (50.7%) of these patients were BRAF mutation positive. BRAF mutation was associated with larger tumor size (OR: 1.64; 95% CI: 1.16–2.32), multifocality (OR: 1.58; 95% CI: 1.25–2.00), ETE (OR: 2.59; 95% CI: 2.03–3.29), LNM (OR: 1.73; 95% CI: 1.14–2.62), advanced stage (OR: 2.03; 95% CI: 1.14–3.64) and TCVPTMC (OR: 5.07; 95% CI: 1.49–17.27; P=0.009). Additionally, the BRAF mutation was found to be not associated with age, gender, concomitant hashimoto thyroiditis or nodular goiter (P>0.05 for all). This meta-analysis revealed that in patients with PTMC, BRAF mutation is associated with tumor size, multifocality, ETE, LNM, advanced stage and TCVPTMC, and it may be used as a predictive factor for prognosis of PTMC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin, 2004,54(1):8–29

    Article  PubMed  Google Scholar 

  2. Lloyd R, De Lellis R, Heitz P, et al. World Health Organization classification of tumours: pathology and genetics of tumours of the endocrine organs. Lyon, France: IARC Press International Agency for Research on Cancer, 2004,48–106

    Google Scholar 

  3. Chow SM, Law SC, Chan JK, et al. Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality. Cancer. 2003(98):31–40

    Google Scholar 

  4. Cappelli C, Castellano M, Braga M, et al. Aggressiveness and outcome of papillary thyroid carcinoma (PTC) versus microcarcinoma (PMC): a mono-institutional experience. J Surg Oncol, 2007,95:555–560

    Article  CAS  PubMed  Google Scholar 

  5. Liou MJ, Lin JD, Chung MH, et al. Renal metastasis from papillary thyroid microcarcinoma. Acta Otolaryngol, 2005,125:438–442

    Article  CAS  PubMed  Google Scholar 

  6. Arora N, Turbendian HK, Kato MA, et al. Papillary thyroid carcinoma and microcarcinoma: is there a need to distinguish the two? Thyroid, 2009,19(5):473–477

    Article  PubMed  Google Scholar 

  7. Choi SY, Park HS, Kang MK, et al. The relationship between the BRAFV600E mutation in papillary thyroid microcarcinoma and clinicopathologic factors. World J Surg Oncol, 2013,1199:291–295

    Article  Google Scholar 

  8. Ji YF. Clinical and biological characteristics of papillary thyroid microcarcinoma and the association with BRAF mutation. Shanghai: Thesis of Nankai University, 2008

    Google Scholar 

  9. Kim TY, Kim WB, Song JY, et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol, 2005,63(5):588–593

    Article  CAS  Google Scholar 

  10. Kwak JY, Kim EY, Chung WY, et al. Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology, 2009,253(3):854–860

    Article  PubMed  Google Scholar 

  11. Lee XL, Gao M, Ji YF, et al. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol, 2009,16(2):240–245

    Article  PubMed  Google Scholar 

  12. Lin KL, Wang OC, Zhang XH, et al. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol, 2010,17(12):3294–3300

    Article  PubMed  Google Scholar 

  13. Rossi ED, Martini M, Capodimonti S, et al. BRAF(V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma. Cancer, 2013,121(6):291–297

    CAS  Google Scholar 

  14. Virk RK, Dyke ALV, Finkelstein A, et al. BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation. Mod Pathol, 2013,26(1):62–70

    Article  CAS  PubMed  Google Scholar 

  15. Walczyk A, Kowalska A, Kowalik A, et al. The BRAFV600E mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome? Clin Endocrinol, 2014,80(6):899–904

    Article  CAS  Google Scholar 

  16. Kim SJ, Lee KE, Myong JP, et al. BRAFV600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg, 2012,36(2):310–317

    Article  PubMed  Google Scholar 

  17. Li C, Lee KC, Schneider EB, et al. BRAFV600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J ClinEndocrinolMetab, 2012,97(12):4559–4570

    Article  CAS  Google Scholar 

  18. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAFV600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer, 2007,110(1):38–46

    Article  PubMed  Google Scholar 

  19. Tufano RP, Teixeira GV, Bishop J, et al. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine, 2012,91(5):274–286

    Article  CAS  PubMed  Google Scholar 

  20. Kim TH, Park YJ, Lim JA, et al. The association of the BRAF (V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer, 2012,118(7):1764–1773

    Article  CAS  PubMed  Google Scholar 

  21. Clarke M, Horton R. Bringing it all together: Lancet-Cochrane collaborate on systematic reviews. Lancet, 2001,357(9270):1728

    Article  CAS  PubMed  Google Scholar 

  22. Lupi C, Giannini R, Ugolini C, et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab, 2007,92(11):4085–4090

    Article  CAS  PubMed  Google Scholar 

  23. Frasca F, Nucera C, Pellegriti G, et al. BRAFV600E mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer, 2008,15(6):191–205

    Article  CAS  PubMed  Google Scholar 

  24. Mussazhanova Z, Matsuda K, Naruke Y, et al. Significance of p53-binding protein 1 (53BP1) expression in thyroid papillary microcarcinoma: association with BRAFV600E mutation status. Histopathology, 2013,63(5):726–734

    PubMed  Google Scholar 

  25. Kurtulmus N, Duren M, Ince U, et al. BRAFV600E mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness. Endocrine, 2012,42(2):404–410

    Article  CAS  PubMed  Google Scholar 

  26. Marchetti I, Iervasi G, Mazzanti CM, et al. Detection of the BRAFV600E mutation in fine needle aspiration cytology of thyroid papillary microcarcinoma cells selected by manual macrodissection: an easy tool to improve the preoperative diagnosis. Thyroid, 2012,22(3):292–298

    Article  CAS  PubMed  Google Scholar 

  27. Chung SY, Lee JS, Lee H, et al. Cytomorphological factors and braf mutation predicting risk of lymph node metastasis in preoperative liquid-based fine needle aspirations of papillary thyroid carcinoma. Acta Cytol, 2013,57(3):252–258

    Article  CAS  PubMed  Google Scholar 

  28. Jung CK, Kang YG, Bae JS, et al. Unique patterns of tumor growth related with the risk of lymph node metastasis in papillary thyroid carcinoma. Mod Pathol, 2010,23(8):1201–1208

    Article  PubMed  Google Scholar 

  29. Min HS, Choe G, Kim SW, et al. S100A4 expression is associated with lymph node metastasis in papillary microcarcinoma of the thyroid. Mod Pathol, 2008,21(6):748–755

    Article  CAS  PubMed  Google Scholar 

  30. Rodolico V, Cabibi D, Pizzolanti G, et al. BRAFV600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid or 1 cm and their paired lymph node metastases. Cancer, 2007,110(6):1218–1226

    Article  PubMed  Google Scholar 

  31. Schulten HJ, Salama S, Al-Mansouri Z, et al. BRAF mutations in thyroid tumors from an ethnically diverse group. Hered Cancer Clin Pract, 2012,10(1):10

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Noguchi S, Yamashita H, Uchino S, et al. Papillary microcarcinoma. World J Surg, 2008,32(5):747–753

    Article  PubMed Central  PubMed  Google Scholar 

  33. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer, 2005,12(2):245–262

    Article  CAS  PubMed  Google Scholar 

  34. Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg, 2007,246(3):466–470

    Article  PubMed Central  PubMed  Google Scholar 

  35. Xu X, Quiros RM, Gattuso P, et al. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res, 2003,63(15):4561–4567

    CAS  PubMed  Google Scholar 

  36. Ito Y, Fukushima M, Kihara M, et al. Investigation of the prognosis of patients with papillary thyroid carcinoma by tumor size. Endocr J, 2012,59(6):457–464

    Article  PubMed  Google Scholar 

  37. Kasai N, Sakamoto A. New subgrouping of small thyroid carcinomas. Cancer, 1987,60(8):1767–1770

    Article  CAS  PubMed  Google Scholar 

  38. Giordano D, Gradoni P, Oretti G, et al. Treatment and prognostic factors of papillary thyroid microcarcinoma. Clin Otolaryngol, 2010,35(2):118–124

    Article  CAS  PubMed  Google Scholar 

  39. Bernet V. Approach to the patient with incidental papillary microcarcinoma. J ClinEndocrinol Metab, 2010,95(8):3586–3592

    Article  CAS  Google Scholar 

  40. Yu XM, Lloyd R, Chen H. Current treatment of papillary thyroid microcarcinoma. Adv Surg, 2012,46(32):191–203

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China

    Yu-jia Ma  (马禹佳), Xiu-ling Deng  (邓秀玲) & Hui-qing Li  (黎慧清)

Authors
  1. Yu-jia Ma  (马禹佳)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiu-ling Deng  (邓秀玲)
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hui-qing Li  (黎慧清)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hui-qing Li  (黎慧清).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ma, Yj., Deng, Xl. & Li, Hq. BRAFV600E mutation and its association with clinicopathological features of papillary thyroid microcarcinoma: A meta-analysis. J. Huazhong Univ. Sci. Technol. [Med. Sci.] 35, 591–599 (2015). https://doi.org/10.1007/s11596-015-1476-4

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-015-1476-4

Key words

Search

Navigation